SEPTRA (sulfamethoxazole; trimethoprim) by Monarch Therapeutics is clinical pharmacology sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. First approved in 1981.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
SEPTRA is a fixed-dose combination of sulfamethoxazole and trimethoprim, a synergistic antibiotic used to treat bacterial and parasitic infections including UTIs, PCP prophylaxis, and certain respiratory infections. The drug works via sequential inhibition of bacterial folate synthesis: sulfamethoxazole inhibits dihydropteroate synthase while trimethoprim inhibits dihydrofolate reductase. It is rapidly absorbed orally with peak levels occurring 1–4 hours after administration and renal excretion as the primary elimination route.
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting the brand team is likely in defensive and generic-transition planning mode with potential workforce restructuring.
CLINICAL PHARMACOLOGY Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized…
Worked on SEPTRA at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients
Working on SEPTRA as a pharma professional typically involves defensive positioning, payer negotiations, and transition planning as the product approaches or enters the LOE phase. Career growth is limited; roles tend to focus on margin protection, generic conversion strategies, and maintaining market share against erosion rather than innovation or expansion.